DOI: 10.1111/bju.16248 ISSN: 1464-4096
Added value of randomized biopsy to mpMRI‐targeted biopsy of the prostate in a contemporary cohort
Michael Chaloupka, Nikolaos Pyrgidis, Benedikt Ebner, Yannic Volz, Paulo L. Pfitzinger, Elena Berg, Benazir Enzinger, Michael Atzler, Troya Ivanova, Dirk‐André Clevert, Alexander Buchner, Christian G. Stief, Maria Apfelbeck- Urology
Objective
To assess the added value of concurrent systematic randomized ultrasound‐guided biopsy (SBx) to multiparametric magnetic resonance imaging (mpMRI)‐targeted biopsy and the additional rate of overdiagnosis of clinically insignificant prostate cancer (ciPCa) by SBx in a large contemporary, real‐world cohort.